GlycoMimetics focuses on therapies for cancers and inflammatory diseases in the US. It develops uproleselan to treat acute myeloid leukemia (AML) with chemotherapy. The company completed a phase 3 trial for relapsed/refractory AML. Other programs include GMI-1687 for vaso-occlusive crisis and GMI-2093 for galectin-3. Its portfolio also includes GMI-1359 targeting e-selectin and chemokine receptor for osteosarcoma treatment. The company has a research agreement with the National Cancer Institute and a collaboration with Apollomics (Hong Kong) Limited. GlycoMimetics was incorporated in 2003 and is headquartered in Rockville, Maryland.
| Indicator | Value |
|---|---|
| PER | 31.6 |
| EV/EBITDA | 10.3 |
| Price/Free Cash Flow' | 31.2 |
| ROIC | 11.2% |
| Net Debt/EBITDA | 1.5 |